{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:53:49Z","timestamp":1791219229956,"version":"4.1.0"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T00:00:00Z","timestamp":1748995200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Cases with massive (diameter \u226510\u2009cm) hepatocellular carcinomas (HCCs) are uncommon and typically have poor outcomes; however, conversion therapy offers a beacon of hope for remission in patients with massive unresectable HCCs. Recently, immune checkpoint inhibitors (ICIs) have been used in combination with other treatment modalities to improve the response rates to conversion therapies, yet the safety and generalizability of this combination have not been extensively validated. Herein, we report a man with a chief complaint of abdominal pain who was diagnosed with massive unresectable HCC. Notably, the patient successfully underwent curative surgery after quadruple conversion therapy using tislelizumab (an ICI), lenvatinib, transarterial chemoembolization, and hepatic arterial infusion chemotherapy directed by a multidisciplinary team. With a complete response achieved, this case demonstrated the major potential of this combination regimen for HCC, and the remarkable efficacy was also reflected by substantial reductions in both alpha-fetoprotein and des-gamma-carboxy prothrombin overall. Nevertheless, transient increases in both biomarkers (tumor marker pseudoprogression) were observed within the first three weeks after initiating ICI treatment. Furthermore, the patient developed a biliary stricture, which resolved after discontinuing the ICI and was ultimately assessed as an immune-related adverse event. Therefore, in the context of combination therapy, further evaluation of the robustness of tumor markers is warranted, and it is crucial for clinicians to be mindful of potential immune-related adverse events.<\/jats:p>","DOI":"10.3389\/fimmu.2025.1529016","type":"journal-article","created":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:37:49Z","timestamp":1749015469000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Tumor marker pseudoprogression and immune-related cholangitis during conversion therapy for massive hepatocellular carcinoma: a case report"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaodong","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuangying","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingling","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huayu","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xudong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huanjun","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rongfeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelei","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,6,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e3283644c49","article-title":"Features of massive hepatocellular carcinomas","volume":"26","author":"Carr","year":"2014","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.4240\/wjgs.v15.i2.273","article-title":"Does size matter for resection of giant versus non-giant hepatocellular carcinoma? A meta-analysis","volume":"15","author":"Lee","year":"2023","journal-title":"World J Gastrointest Surg"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/ccr3.7533","article-title":"Conversion therapy for massive hepatocellular carcinoma: A case report and literature review","volume":"11","author":"Zhou","year":"2023","journal-title":"Clin Case Rep"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1073531","article-title":"Conversion therapy for advanced hepatocellular carcinoma with vascular invasion: a comprehensive review","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"298","DOI":"10.14218\/jcth.2023.00403","article-title":"Improving the conversion success rate of hepatocellular carcinoma: focus on the use of combination therapy with a high objective response rate","volume":"12","author":"Chen","year":"2024","journal-title":"J Clin Transl Hepato"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-021-00573-2","article-title":"Immunotherapies for hepatocellular carcinoma","volume":"19","author":"Llovet","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/jso.27545","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: A review of current clinical trials","volume":"129","author":"Gamboa","year":"2024","journal-title":"J Surg Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00147-4","article-title":"Immune checkpoint inhibitors in hepatocellular carcinoma: emerging challenges in clinical practice","volume":"8","author":"Pinter","year":"2023","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2020.1762562","article-title":"Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience","volume":"20","author":"Vitale","year":"2020","journal-title":"Expert Opin Biol Ther"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.cn501113-20220823-00432","article-title":"A retrospective controlled study of TACE-HAIC-targeted-immune quadruple therapy for intermediate and advanced-stage hepatocellular carcinoma","volume":"30","author":"Li","year":"2022","journal-title":"Chin J Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000000256","article-title":"TACE-HAIC combined with targeted therapy and immunotherapy versus TACE alone for hepatocellular carcinoma with portal vein tumour thrombus: a propensity score matching study","volume":"109","author":"Yuan","year":"2023","journal-title":"Int J Surg"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J Hepatol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/cm9.0000000000002950","article-title":"Chinese expert consensus on the overall management of liver function in conversion therapy for liver cancer (2022 edition)","volume":"136","author":"Meng","year":"2023","journal-title":"Chin Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn-21-328","article-title":"Chinese expert consensus on conversion therapy for hepatocellular carcinoma (2021 edition)","volume":"11","author":"Sun","year":"2022","journal-title":"Hepatobil Surg Nutr"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101381","article-title":"Elevated tumor markers for monitoring tumor response to immunotherapy","volume":"46","author":"Yang","year":"2022","journal-title":"eClinicalMedicine"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.02.014","article-title":"EASL Clinical Practice Guidelines: Drug-induced liver injury","volume":"70","author":"Andrade","year":"2019","journal-title":"J Hepatol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.jhep.2019.09.026","article-title":"mRECIST for HCC: Performance and novel refinements","volume":"72","author":"Llovet","year":"2020","journal-title":"J Hepatol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.adengl.2019.05.021","article-title":"Using the common terminology criteria for adverse events (CTCAE \u2013 version 5.0) to evaluate the severity of adverse events of anticancer therapies","volume":"112","author":"Freites-Martinez","year":"2021","journal-title":"Actas Dermo-Sifilogr"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1097\/meg.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24055002","article-title":"An immunological perspective on the mechanism of drug induced liver injury: focused on drugs for treatment of hepatocellular carcinoma and liver transplantation","volume":"24","author":"Lee","year":"2023","journal-title":"Int J Mol Sci"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00730-3","article-title":"Clinical and translational attributes of immune-related adverse events","volume":"5","author":"Suijkerbuijk","year":"2024","journal-title":"Nat Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000210098.28876.66","article-title":"Chemotherapy-induced sclerosing cholangitis: long-term response to endoscopic therapy","volume":"40","author":"Alazmi","year":"2006","journal-title":"J Clin Gastroenterol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-009-9781-6","article-title":"Main bile duct stricture occurring after transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"33","author":"Miyayama","year":"2010","journal-title":"Cardiovasc Intervent Radiol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2147\/cmar.S303172","article-title":"The risk assessment and clinical research of bile duct injury after transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"13","author":"Xu","year":"2021","journal-title":"Cancer Manag Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12071","article-title":"Blood supply of the main bile duct from the caudate artery and medial subsegmental artery of the hepatic artery: Evaluation using images obtained during transcatheter arterial chemoembolization for hepatocellular carcinoma","volume":"43","author":"Miyayama","year":"2013","journal-title":"Hepatol Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-019-01116-x","article-title":"Lenvatinib: A review in hepatocellular carcinoma","volume":"79","author":"Al-Salama","year":"2019","journal-title":"Drugs"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2019.05.004","article-title":"Management of adverse events associated with tyrosine kinase inhibitors: Improving outcomes for patients with hepatocellular carcinoma","volume":"77","author":"Rimassa","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005635","article-title":"Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events","volume":"10","author":"Coukos","year":"2022","journal-title":"J Immunother Cancer"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100719","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14043","article-title":"Outcomes of immune checkpoint inhibitor-induced liver toxicity managed by hepatologists in a multidisciplinary toxicity team","volume":"54","author":"Ito","year":"2024","journal-title":"Hepatol Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16194","article-title":"Conversion therapy for advanced hepatocellular carcinoma in the era of precision medicine: Current status, challenges and opportunities","volume":"115","author":"Wang","year":"2024","journal-title":"Cancer Sci"},{"key":"B33","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1055\/s-0043-1776127","article-title":"Unraveling the complexities of immune checkpoint inhibitors in hepatocellular carcinoma","volume":"43","author":"Han","year":"2023","journal-title":"Semin Liver Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11912-020-00974-z","article-title":"Immune response evaluation and treatment with immune checkpoint inhibitors beyond clinical progression: response assessments for cancer immunotherapy","volume":"22","author":"Mushti","year":"2020","journal-title":"Curr Oncol Rep"},{"key":"B35","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejca.2017.10.017","article-title":"Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria","volume":"88","author":"Tazdait","year":"2018","journal-title":"Eur J Cancer"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.75.1644","article-title":"Immune-modified response evaluation criteria in solid tumors (imRECIST): refining guidelines to assess the clinical benefit of cancer immunotherapy","volume":"36","author":"Hodi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1165538","article-title":"Case Report: A case of hepatocellular carcinoma with aberrant right hepatic artery treated with transarterial chemoembolization and infusion chemotherapy separately to bilobar lesion combining with systemic therapies and sequential hepatectomy","volume":"13","author":"Wei","year":"2023","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-018-0902-0","article-title":"A case of gastric cancer with delayed onset of tumor reduction effect by nivolumab therapy","volume":"12","author":"Satoyoshi","year":"2019","journal-title":"Clin J Gastroenterol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.jcrt_1050_22","article-title":"Pseudoprogression during immunotherapy for gastric adenocarcinoma: A case report and literature review","volume":"19","author":"Zhang","year":"2023","journal-title":"J Cancer Res Ther"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.cld.2015.01.005","article-title":"Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders","volume":"19","author":"Wong","year":"2015","journal-title":"Clin Liver Dis"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2022.00285","article-title":"Diagnostic efficacy and possible underlying mechanisms of noninvasive clinical markers in hepatocellular carcinoma","volume":"11","author":"Fu","year":"2023","journal-title":"J Clin Transl Hepato"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-023-04997-4","article-title":"Development and validation of a diagnostic model for AFP-negative hepatocellular carcinoma","volume":"149","author":"Yu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0212","article-title":"Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region","volume":"29","author":"Kim","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110019","article-title":"Blood biomarkers predict outcomes in patients with hepatocellular carcinoma treated with immune checkpoint Inhibitors: A pooled analysis of 44 retrospective sudies","volume":"118","author":"Zhang","year":"2023","journal-title":"Int Immunopharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15112927","article-title":"Early prediction of response focused on tumor markers in atezolizumab plus bevacizumab therapy for hepatocellular carcinoma","volume":"15","author":"Tanabe","year":"2023","journal-title":"Cancers"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1529016\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,4]],"date-time":"2025-06-04T05:37:50Z","timestamp":1749015470000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2025.1529016\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,4]]},"references-count":45,"alternative-id":["10.3389\/fimmu.2025.1529016"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2025.1529016","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,4]]},"article-number":"1529016"}}